Risk-reducing surgery for individuals with cancer-predisposing germline pathogenic variants and no personal cancer history: a review of current UK guidelines.

"Competing interests EC has participated in advisory boards for Astra-Zeneca, Eli-Lilly, Pfizer and Nanostring, and is on an expert panel for the World Cancer Research Fund. EC has received an honorarium from Astra-Zeneca, Eli-Lilly, Novartis, Pfizer and Roche and an educational grant from Daiichi-Sankyo. EC and RIC have received research support from SECA and Astra-Zeneca. The remaining authors declare no competing interests."

"Funding RLM was supported by the University of Southampton National Institute of Health Research Academic Foundation Programme. MT was supported by the Cancer Research UK Catalyst Award CanGene-CanVar (C61296/A27223) and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). JRON is supported in part by the CRUK Cambridge Centre Thoracic Cancer programme (CTRQQR-2021\100012). EC and RIC have received research support from SECA and Astra-Zeneca (70053237). The views expressed are those of the authors and not necessarily the NIHR or the Department of Health and Social Care."